Establishment of functional and stable collaterals in the ischemic myocardium is crucial to restoring cardiac function after myocardial infarction. Here, we show that only dual delivery of a combination of angiogenic and arteriogenic factors to the ischemic myocardium could significantly reestablish stable collateral networks and improve myocardial perfusion and function. A combination of FGF-2 with PDGF-BB, two factors primarily targeting endothelial cells and vascular smooth muscle cells, remarkably promotes myocardial collateral growth and stabilizes the newly formed collateral networks, which significantly restore myocardial perfusion and function. Using various members of the PDGF family together with FGF-2 in an angiogenesis assay, we demonstrate that PDGFR-␣ is mainly involved in angiogenic synergism, whereas PDGFR-␤ mediates vessel stability signals. Our findings provide conceptual guidelines for the clinical development of proangiogenic/arteriogenic factors for the treatment of ischemic heart disease.
A therosclerosis-induced coronary artery disease is the leading cause of morbidity and mortality in Western societies and increases at an alarming rate in developing countries (1) . Usually, progressive atherosclerosis results in plaque rupture and thrombosis of major coronary arteries, leading to angina, myocardial infarction, and heart failure (2) . Except for surgical interventions, an effective therapeutic method for treatment has been lacking. Although delivery of proangiogenic factors to the ischemic myocardium to stimulate collaterogenesis and to improve myocardial perfusion and function is a straightforward idea proposed for Ͼ30 years, clinical evaluation of these individual proangiogenic molecules has produced unfulfilled promises (3) (4) (5) . After more than a decade of clinical practice with different single proangiogenic factors for the treatment of ischemic disorders, almost all large randomized, double-blinded, and placebo-controlled human trials have proven to be nonbeneficial (6) (7) (8) .
The clinical failures with this attractive approach have raised several unresolved fundamental issues regarding the basic mechanisms of cardiovascular biology. These include the underlying mechanisms of angiogenesis versus arteriogenesis, choice of proangiogenic agents, monotherapy versus combinatorial therapy, appropriate animal models for preclinical evaluation, optimal drug release systems, and time line of delivery. For improvement of perfusion of high-oxygenated blood in ischemic tissues, it is essential to reestablish functional arterial vascular networks, which should remain stable long-term. Most previous preclinical and clinical studies on the development of proangiogenic therapies for treating ischemic myocardium have been based on monotherapeutic approaches (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . These approaches usually lack rationales for understanding the molecular mechanisms of arteriogenesis, for defining molecular targets of the deliverable proangiogenic factors, and for selection of optimal angiogenic/arteriogenic agents. In addition, most studies have focused on evaluation of the therapeutic efficacy of vascular endothelial growth factor (VEGF) A, which primarily targets the endothelial cell compartment (5, 12, 17, 21, 22) . Unlike rodents and dogs, pigs usually lack sufficient native collaterals to prevent major infarction after coronary artery occlusion (23) (24) (25) . Thus, the pig myocardial infarction model is the most relevant and ideal animal system to human coronary artery disease.
We have recently shown that a combination of two non-VEGF growth factors, fibroblast growth factor 2 (FGF-2) and plateletderived growth factor BB (PDGF-BB), induces angiogenic synergy and vessel stability in rodents (26) . FGF-2 is the prototype of a structurally related growth factor family consisting of 24 known members (27) (28) (29) . Although the release of the signal peptide-less FGF-2 from its synthetic cells remains enigmatic, this growth factor plays a crucial role extracellularly in the regulation of the growth of its target cells including endothelial cells. Interestingly, administration of FGF-2 in vivo selectively stimulates angiogenesis but not other tissue growth (29) . In contrast to FGF-2, members of the PDGF family act mainly on vascular mural cells including pericytes and vascular smooth muscle cells (VSMC) (30) (31) (32) . Whereas PDGF-AA specifically interacts with the homodimeric cell-surface tyrosine kinase receptor, PDGF receptor ␣ (PDGFR-␣), PDGF-BB interacts with both homodimeric and heterodimeric PDGFR-␣ and PDGFR-␤ complexes (30) . It is known that PDGFR-␤ plays an essential role in the stabilization of blood vessels via the recruitment of mural cells/VSMC onto the nascent vasculature (33) . Thus, PDGFs, and particularly PDGF-BB, are important arteriogenic factors for stabilization of the newly formed vasculature. PDGFR-␣ is also expressed in blood-vessel endothelial cells (34) . The rationale of our present work is to combine arteriogenic factors, such as PDGF-BB, with angiogenic factors, such as FGF-2, for therapeutic evaluation in a pig myocardial infarction model.
Results
Dual Delivery of PDGF-BB/FGF-2 and PDGF-AB/FGF-2 but Not PDGF-AA/FGF-2 Promotes Vessel Stability. To study the role of various members of the PDGF family in a combination with FGF-2 in promoting angiogenic synergisms and the formation of stable vessels, a slow-release polymer containing PDGF-AA/FGF-2, PDGF-AB/FGF-2, or PDGF-BB/FGF-2 was implanted into the mouse cornea. Both FGF-2 and PDGFs are strong heparinbinding growth factors, which can be released by slow-release polymers with heparin-binding properties. Sucrose aluminum octosulfate possesses a strong heparin-binding affinity that binds to both factors and serves as a slow-release material. All three combinations of growth factors released by this polymeric delivery system synergistically induced angiogenesis as compared with single growth factor-induced angiogenesis ( Fig. 1 A-H) . These data validate our previous findings that a combination of FGF-2 with PDGF-BB synergistically induces angiogenesis (26) . The avascular feature of the corneal tissue allowed us to noninvasively follow blood vessel stability long-term. At day 70 after implantation, PDGF-AA/FGF-2-induced vessels were almost completely regressed, suggesting that this combination is unable to stabilize the newly formed vasculature (Fig. 1I) . Interestingly, both PDGF-AB/FGF-2-and PDGF-BB/FGF-2-induced corneal vascular networks remained stable at this and later time points ( Fig. 1 J and K) . It should be emphasized that the primitive nascent vasculatures induced by both combinations underwent remarkable remodeling, resulting in well defined, stable, and mature vascular networks at later time points. These findings demonstrate that only PDGF-AB/FGF-2 or PDGF-BB/ FGF-2, but not PDGF-AA/FGF-2, is able to stabilize the newly formed vasculature, although all three combinations promote angiogenic synergisms. We thus chose a combination of PDGF-BB/FGF-2 for the therapeutic evaluation and further studies.
Establishment of Stable Collateral Networks by PDGF-BB/FGF-2 in the
Ischemic Myocardium. To evaluate the combinatorial therapeutic approach in a clinically relevant animal model, we developed a pig myocardial infarction model based on a modified protocol in which left anterior descending (LAD) coronary artery was ligated to induce myocardial infarction. Single or combinatorial angiogenic/arteriogenic factors were delivered to the ischemic region of the myocardium at the time of infarction by using a slow-release polymer consisting of sucrose aluminum octosulfate and hydron possessing heparin binding activity. This slow-release polymer composition was the same as that previously used in our mouse corneal micropocket assay and proven to effectively release PDGF-BB and FGF-2 ( Fig. 1) . Coronary angiographic analysis showed that at week 6 PDGF-BB/FGF-2 significantly induced myocardial collateral growth as compared with various individual angiogenic or arteriogenic factor-treated myocardium. These newly established collaterals formed vascular net- works proximally and distally from the ligation site ( Fig. 2 
E-H).
To study the stability of these newly established collateral networks, coronary angiography was again performed on week 14 after treatment. Remarkably, the PDGF-BB/FGF-2-induced collaterals had developed into well established coronary arterials appearing as corkscrew-shaped vessels forming vascular networks downstream from the ligation site, indicating the reestablished collaterals remained stable ( Fig. 2 L and P) . Although FGF-2 alone seemed to induce marginal collateral growth, PDGF-BB alone did not induce any detectable collateral growth at either time point in the ischemic myocardium as compared with those promoted by buffer alone (Fig. 2 
I-K and M-O).
For quantitative evaluation, collateral index analysis was performed at weeks 6 and 14 according to a standard protocol using Rentrop's grading scales (35) . The baseline collateral indexes in all four groups were indistinguishable. At week 6, both FGF-2-and PDGF-BB/FGF-2-treated groups exhibited remarkable increases of collaterals indexes (P ϭ 0.018 and P ϭ 0.001, respectively; Fig. 3 A-D) as compared with their baseline indexes. Although the PDGF-BB-treated group showed a trend toward an improvement of the collateral index, this marginal increase was statistically insignificant as compared with its baseline index (P ϭ 0.058). Additionally, the collateral index was significantly higher in the PDGF-BB/FGF-2 together-treated group as compared with those of FGF-2-or PDGF-BB alonetreated groups (FGF-2, P ϭ 0.037; PDGF-BB, P ϭ 0.021) or PBS alone (P ϭ 0.002). Long-term follow-up analysis showed that the collateral index continued to increase and remained stable in the PDGF-BB/FGF-2-treated group (Fig. 3 E-H) . These data are consistent with the results obtained in our corneal angiogenesis model demonstrating that PDGF-BB and FGF-2 together promote the establishment of long-lasting blood vessels.
To further validate the presence of newly formed collaterals, various growth factor-treated ischemic myocardium were immunologically stained with an anti-␣ smooth muscle cell actin (␣-SMA) antibody. Consistent with the coronary angiographic analysis, high numbers of arterial vessels were detected in the PDGF-BB/FGF-2-treated myocardium at week 14 posttreatment as compared with those of single factor-treated or control samples (Fig. 4 A-D and Q) . Although PDGF-BB-or FGF-2-treated myocardium seemed to contain higher numbers of collaterals as compared with the buffertreated group, there were no statistically significant differences between these groups (Fig. 4 A-C and Q) . To determine the degree of vessel maturation and correlate association between blood vessels with VSMC, various factor-treated myocardium were examined by double immunohistochemistry staining for von Willebrand factor (vWF) and ␣-SMA. At week 14 after treatment, Ͼ80% of all of the myocardial vessels were ␣-SMA positive in the PFGF-BB/FGF-2 together-treated group, whereas significantly fewer ␣-SMA-positive vessels were detected in the PDGF-BB, FGF-2, or buffer alone-treated myocardium (Fig. 4 E-P and R) . These results demonstrate that dual delivery of PDGF-BB/FGF-2 synergistically promotes arteriogenesis, arterial maturation, and stabilization of myocardial collateral networks.
Improvement of Regional Myocardial Blood Flow.
To study the improvement of cardiac function after monotherapy or combi- natorial therapy, the myocardial blood flow (MBF) was assessed by a colored microsphere method. Before treatment, the basal levels of MBF in the LAD territory were indistinguishable among all groups (Fig. 5A) . At week 6, there were no differences in MBF in single growth factor-treated myocardium as compared with the buffer-treated group (Fig. 5B) . Notably, the PDGF-BB/FGF-2 together-treated group exhibited remarkably higher MBF than either factor alone-treated myocardium (Fig. 5B) . The high level of MBF persisted long-term in the PDGF-BB/FGF-2-treated group, and no reduction of MBF was observed at the end point of the experiment (14 weeks) (Fig. 5C ). Statistical analysis of these data by factorial analysis of variance showed that MBF in the PDGF-BB/FGF-2 together-treated group was markedly greater than the sum effects obtained from two factors alone-treated myocardium (F ϭ 7.317, P ϭ 0.011, at week 6; and F ϭ 4.930, and P ϭ 0.034, at week 14). These findings indicate that dual delivery of PDGF-BB/FGF-2 synergistically improves local blood flow in the ischemic myocardium, indicating that the high numbers of newly formed collateral networks are functional.
Improvement of Global and Regional Myocardial Functions. Echocardiography was performed to monitor global and regional myocardial function. Measurement of left ventricular ejection fraction (LVEF), a standard parameter to monitor global myocardial contractile function, showed that the basal cardiac dysfunction was indistinguishable among all groups before treatment (Fig. 5D) . At week 14 after treatment, a significant improvement of LVEF was observed in the PDGF-BB/FGF-2-treated group as compared with the buffer-treated group (Fig. 5D) . In contrast, neither single growth factor-treated group showed significant improvements of LVEF, consistent with the MBF findings. To assess regional wall motion, left ventricular systolic wall thickening (WT%) was calculated. Similar to LVEF results, PDGF-BB and FGF-2 alone-treated groups did not show any significant improvement in WT% as compared with buffer controls. In contrast, the PDGF-BB/FGF-2-treated group significantly improved the WT% as compared with either buffer-or single factor-treated groups (Fig. 5E ). These findings demonstrate that dual delivery of PDGF-BB/FGF-2 remarkably stimulates myocardial collaterogenesis, leading to a significant improvement of regional as well as global myocardial contractile functions.
Discussion
We have shown here that a protein-based angiotherapeutic approach, based on dual delivery of arteriogenic and angiogenic factors, significantly improves myocardial collateral growth, blood perfusion, and cardiac function in a pig ischemic myocardial model. Both therapeutic angiogenesis and antiangiogenic therapies have received significant attentions as they hold great promises for the treatment of the most common and severe human diseases including malignant, ophthalmological, and cardiovascular disorders. After the first FDA-approved antiangiogenesis drug, bevacizumab, several other antiangiogenic drugs targeting VEGF or its signaling components, including pegaptanib, sunitinib, and ranibizumab, have very recently been approved (36) (37) (38) (39) . The failures of clinical trials with proangiogenic factors for the treatment of ischemic diseases have left the therapeutic angiogenesis field far behind (4, 6). Although targeting single angiogenic factors such as VEGF for suppression of angiogenesis is an effective approach for therapy, the delivery of single angiogenic factors to ischemic tissues has failed to conclusively show a therapeutic benefit, suggesting that single angiogenic or arteriogenic factors are unable to accomplish the complex process of arteriogenesis (3, 4, 6, 40) . Among many possible reasons for these clinical failures, the choice of optimal biological agents is a crucial issue for successful therapy.
Selection of optimal angiogenic/arteriogenic molecules should consider the basic process of arteriogenesis, which builds up functional arterial networks. Unlike angiogenesis, arteriogenesis refers to the process of maturation, de novo formation and/or remodeling of collateral conduits (41) . Previous studies in rodents have suggested that remodeling of preexisting vessels is pivotal to the establishment of arterial networks (42) . Because arterial blood vessels are composed of both endothelial cells and VSMC, the rationale of our present study was to combine both angiogenic and arteriogenic factors, thus targeting endothelial cells and VSMC for de novo formation and remodeling of myocardial collaterals (Fig. 6) . For this purpose, we have investigated various combinations of different angiogenic and arteriogenic factors for promoting angiogenesis and arteriogenesis in our in vivo animal models. Our previous studies have indicated that only the combination PDGF-BB/FGF-2, but not PDGF-BB/VEGF or FGF-2/VEGF, is able to synergistically induce angiogenesis and arteriogenesis (26) . This work further suggests that the interplay between various angiogenic and arteriogenic factors for promoting arteriogenesis is specifically limited to certain combinations, and that each factor has its own specific molecular partners.
FGF-2 is one of the most potent angiogenic factors, primarily targeting vascular endothelial cells as a mitogenic and survival factor (29) . FGF-2 has been reported to up-regulate the expression levels of PDGFRs in endothelial cells (26) . Although PDGF-BB primarily acts on VSMC and pericytes via PDGFR-␤, the PDGFR-␣ for this ligand is also expressed in endothelial cells, suggesting its direct role in regulation of angiogenesis (34, 43) . In this regard, it is not surprising that a combination of FGF-2 with PDGF-AA promotes angiogenic synergism (Fig. 6) . Unlike PDGFR-␣, PDGFR-␤ is mainly distributed in VSMC and controls the growth and recruitment of VSMC to endothelial cells (31) . Together with angiopoietin-1, PDGF-BB is considered as a vascular stabilizer (32, 34, 44) . Unexpectedly and surprisingly, our present results show that PDGF-BB is unable to stabilize its own vessels, suggesting that additional factors are required for vessel stability. Our in vivo studies provide compelling evidence that PDGF-BB is required to cooperatively work with FGF-2 for vessel stability (26) . These findings imply that the establishment of stable arterial networks requires a cooperative effort between angiogenic and arteriogenic factors. A simplified model of the interplay between PDGFs and FGF-2 in stimulation of arteriogenesis and vessel stability is presented in Fig. 6 , although it is likely that PDGFR-␤ and PDGFR-␣ also are expressed in endothelial cells and VSMC, respectively.
The underlying cellular and molecular mechanisms of arteriogenesis might involve both de novo formation of new collaterals and remodeling of preexisting collaterals. Whereas coronary angiographic analysis clearly showed the reestablishment of occluded coronary collaterals, immunohistological analysis demonstrated increased numbers of new collaterals in the dual factor-treated group. The simultaneous events of growth and remodeling of arterial vessels require intimate cooperation between PDGF-BB and FGF-2, which should be bioavailable on the same cellular targets. Our dose studies show that the optimal ratio between FGF-2 and PDGF-BB released by sucrose aluminum octosulfate polymers is 4:1. The issue regarding the optimal time line of delivery warrants further study. To the best of our knowledge, the delivery of angiogenic and arteriogenic factors in combination to the ischemic myocardium in big animals has not previously been reported. Because of the lack of native collaterals, the pig myocardial infarction model is probably one of the most relevant preclinical systems to human coronary artery disease (25) . Unfortunately, for several reasons, including high costs, difficulty in obtaining ethics approval, sophisticated operation procedures, and the need for relatively high dosages of angiogenic factors, most previous preclinical studies have been carried out in smaller animals such as rodents and rabbits, which often have native collaterals that prevent major myocardial infarction and lead to significant spontaneous recuperation (45, 46) . Based on our findings in pigs, we speculate that dual delivery of PDGF-BB/FGF-2 to ischemic myocardium would produce beneficial effects in humans, although future studies are needed to validate this assumption.
Taken together, our present study provides an example of applying a combination of arteriogenic and angiogenic factors to the pig ischemic myocardium for establishing stable collateral networks, leading to a remarkable improvement of both blood flow and myocardial function. These findings may open new avenues and serve as a guiding principle for the development of future proangiogenic and arteriogenic therapies for the clinical treatment of myocardial infarction. Animals were randomly divided into four groups (n ϭ 10 pigs per group). Before all experimental procedures, all animals were anesthetized by intramuscular administration of ketamine hydrochloride (20 mg/kg; Heng Rui Medicine, Jiang Su, China) together with i.v. injection of sodium pentobarbital (30 mg/kg; Beijing Chemical Reagent Company, Beijing, China) and were mechanically ventilated with a volume respirator (E100m ventilator; Newport Medical Instruments, Costa Mesa, CA). Median sternotomy was performed to expose the heart followed by incision of the pericardium. Acute myocardial infarction was produced by ligation of the LAD coronary artery distal to its third diagonal branch using a 7.0-prolene suture. Selective left and right angiography, performed through a standard procedure (see below), was made to confirm complete occlusion of the LAD coronary artery and to assess baseline levels of collaterals to assess the collateral index. Immediately after this procedure, 5 ϫ 10 6 red microspheres (10 Ϯ 2 m diameter; E-Z Trac, Los Angeles, CA) were injected into the left ventricle for measurement of regional blood flow levels. Ad- Arteries consist of endothelial cells expressing specific markers such as CD31 (red) and VSMC expressing specific markers such as ␣-SMA (green). FGF-2 primarily acts on FGFRs expressed on endothelial cells in vivo to promote angiogenesis. Both PDGF-AA and PDGF-BB may activate PDGFR-␣ expressed on endothelial cells to induce angiogenesis. When both FGFRs-and PDGFR-mediated-signaling pathways are coactivated simultaneously in endothelial cells by their respective ligands, these two independent signaling systems lead to an angiogenic synergism. VSMC play a crucial role in vessel stability and maturation. PDGF-BB, but not PDGF-AA, activates PDGFR-␤ predominantly expressed on VSMC. FGFRs could also be expressed in VSMC and cooperatively promote vessel stability signals with the PDGFR-␤. Therefore, although both PDGF-AA and PDGF-BB are able to synergistically stimulate angiogenesis together with FGF-2, only PDGF-BB, but not PDGF-AA, in the presence with FGF-2 is able to stabilize the newly formed vasculature and to function as an arteriogenic factor. ditionally, echocardiography was performed in all animals to evaluate baseline global and regional left ventricle function. A slowreleasing pellet of sucrose aluminum sulfate coated with hydron polymer (0.2 ϫ 0.2 cm) containing PBS, 5 g of FGF-2, 10 g of PDGF-BB, or 5 g of FGF-2/10 g of PDGF-BB was attached to an aseptic application (0.5 ϫ 0.5 cm), which was sutured (7.0-prolene) onto the border zone adjacent to the mid and distal LAD coronary artery. After implantation, the pericardium and chest were closed and the animals were allowed to recover from the anesthesia.
Materials and Methods
Angiography and Quantification Analysis of Coronary Collateral Circulation. Six and 14 weeks after treatments, repeated, selective angiography was performed. Under general anesthesia, the animals received a contrast agent, meglumine diatrizoate, through a standard femoral puncture by using digital subtraction angiography (CGO-2100; Wandong Medical Equipment). To precisely assess collateral filling of LAD territory, semiquantification of the collateral coronary circulation was performed with Image ProPlus 5.1 according to the manufacturer's instruction (Media Cybernetics, Silver Spring, MD). Images with the best contrast were selected for analysis for each animal, and the angiographic index was calculated by using a standard protocol based on Rentrop's grading scales. The area of interest (AOI) was defined as a left ventricular region that included neocollaterals and a distal segment of the ligated LAD coronary artery. The profile of the LAD and collateral artery reperfusion were delineated carefully, and total collateral vascular areas were calculated. Each image was recorded three times.
Regional Myocardial Blood Flow. Assessment of regional MBF was carried out before treatment and at the end of weeks 6 and 14 by catheter-guided injection into the left ventricle of 5 ϫ 10 6 red, yellow, and green microspheres. Reference blood samples were simultaneously collected. Recovery of microspheres from tissues and blood was performed according to the manufacturer's instructions.
Echocardiographic Analysis. Two-dimensional echocardiography was used to measure global and regional left ventricular function in all animals with open chest after angiographic assessment before and 14 weeks after treatment using an ultrasound scanner (SONOS 7500; Philips Medical Systems, Andover, MA). Analyses of LVEF and systolic wall thickening (WT%) were performed to determine the global function of the left ventricle and the regional function of the myocardium, respectively. LVEF was determined from the apical two-and four-chamber views by using a modified Simpson's algorithm. Regional wall thickness was measured at end-diastole (the peak of R wave of the ECG) and end-systole (the end of T wave of the ECG) individually on two-dimensional echocardiograms. Left ventricular wall thickness at both end-diastole (DWT) and end-systole (SWT) was measured, and left ventricular systolic wall thickening (WT%) was calculated as WT% ϭ (SWT Ϫ DWT)/DWT ϫ 100%.
Immunohistochemistry. The treated areas of the left ventricle myocardium in the LAD territory were fixed with 3% paraformaldehyde or immediately frozen in liquid nitrogen. To determine vessel density, paraffin-embedded, 5-m sections were incubated with a rabbit anti-vWF antibody or a mouse anti-␣SMA antibody, followed by incubation with secondary antibodies labeled with horseradish peroxidase. Ischemic myocardial sections were also used for detection of vWF/␣SMA double positivity by immunofluorescent analysis. A maturation index (percentage of smooth muscle cellpositive vessels vs. total vessel numbers) was calculated (see SI Methods for detailed information).
